Search

everythinglearnresearchcommunity

for

Search:↓

An AI device for skin cancer was successfully integrated into the NHS, improving diagnosis accuracy and service capacity.

A potential treatment for atopic dermatitis could be to increase PADI1 expression to improve skin barrier function.

Tofacitinib improved hair and nail conditions in a teen with alopecia areata.

Tofacitinib helped psoriasis but not alopecia universalis, needing more research.

Expanding regulatory T cells may help treat alopecia areata by reducing harmful immune cells.

CD4 T cells can cause alopecia areata by activating CD8 T cells to attack hair follicles.

Ritlecitinib is effective for long-term hair regrowth in alopecia areata, especially in females and early treatment.

Activating TLR3 helps improve skin and hair follicle regeneration after wounds.

Chronic refractory alopecia areata has more skin-resident memory T cells, and JAK inhibitors may help reduce them.

IL-17 and certain immune cells are linked to more severe alopecia areata.

The early genes of a specific virus can cause abnormal skin cell growth and hair follicle changes.

Proactive monitoring and management are essential to maximize the benefits of Trastuzumab Deruxtecan while minimizing serious side effects.

Tofacitinib may help regrow hair in severe alopecia areata, but results differ greatly between people.

The study found that analyzing certain cell signaling pathways is not a reliable method to tell apart two types of skin tumors.

TNFα and interleukin-1 blockers reduce skin inflammation from EGFR antibody therapy.

Topical tofacitinib is a safe and effective treatment for autoimmune skin disorders.

PD‐L1 and PD‐L2 may not effectively control immune activation in alopecia areata.

The system improved diabetic wound healing in rats.

Alopecia areata involves unique activation of certain immune cells.

Tofacitinib effectively regrows hair in alopecia areata patients, especially in younger individuals, with manageable side effects.

The document concludes that doctors should recognize congenital triangular alopecia to avoid unnecessary treatments, as it does not respond to steroids like alopecia areata does.

AIRE-deficient rats developed severe autoimmune disease similar to APECED, useful for testing treatments.

TNFα and interleukin-1 blockers reduce skin inflammation from EGFR antibody therapy.

MITF+ melanoma patients are more likely to have multiple melanomas and unique skin patterns.

A Brazilian teenager with severe hair loss had total hair regrowth with no side effects after using tofacitinib.

TLR4 is important in aging-related diseases and could be a new treatment target.

CD8+ T cells re-expressing CD45RA may predict treatment resistance in severe alopecia areata.

The document concludes that DAB389-IL2 is promising for treating refractory cutaneous T-cell lymphoma, but more research is needed on its effectiveness and side effect management.

A new TP63 mutation was found in a baby with EEC syndrome, showing the need for TREC testing to check for immune issues.